Different flavonoids present in the micronized purified flavonoid fraction (Daflon® 500 mg) contribute to its anti-hyperpermeability effect in the hamster cheek pouch microcirculation

International Angiology

Volumn 27, Issue 1, 2008, Pages 81-85

  Paysant, J ^a   Sansilvestri Morel, P ^a   Bouskela, E ^b   Verbeuren, Tony J ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Flavonoids; Microcirculation; Reperfusion injury

Indexed keywords

ALVENOR; ARDIUM; ARVENUM; CAPIVEN; DAFLON; DETRALEX; DIOSMETIN; DIOSMIN; ELATEC; FLAVONOID; FLEBOTROPIN; HESPERIDIN; ISORHOIFOLIN; LINARIN; PLACEBO; UNCLASSIFIED DRUG; VARITON; VENITOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY LEAK SYNDROME; CHEEK POUCH; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HEART MUSCLE ISCHEMIA; MALE; MICROCIRCULATION; MONOTHERAPY; NONHUMAN; REPERFUSION INJURY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CAPILLARY PERMEABILITY; CHEEK; CRICETINAE; DIOSMIN; DRUG COMBINATIONS; DRUG EVALUATION, PRECLINICAL; FLAVONOIDS; GLYCOSIDES; HESPERIDIN; MALE; MICROCIRCULATION; REPERFUSION INJURY;

EID: 42149112242     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Damien G. S5682. Comprimé enrobé dosé à 500 mg de fraction flavonoïque purifiée micronisée comprenant 90 pour cent de diosmine et 10 pour cent de flavonoïdes exprimés en hespéridine. Study Report. 1996. Data on file.
2. Pascarella L. Essentials of Daflon 500 mg: from early valve protection to long-term benefits in the management of chronic venous disease. Curr Pharm Des 2007;13:431-44.
3. Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;48:391-9.
4. Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interaction and microvascular barrier dysfunction in skeletal muscle. Cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc Clin Exp 1997;17 Suppl 1:11-7.
5. Verbeuren TJ. Microvascular adhesion mechanisms in chronic venous insufficiency: a pharmacological approach. In: Schmid-Schönbein GW, Granger N, editors. Molecular basis of microcirculatory disorders. Paris, France: Springer-Verlag; 2003.p.515-28.
6. Bergan JJ, Schmid-Schönbein GW, Coleridge-Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Mechanisms of disease: chronic venous disease. N Engl J Med 2006;355:488-98.
7. Saharay M, Shield DA, Porter JB, Scurr JH, Coleridge-Smith PD. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 1997;26:265-73.
8. Kloner CA, Ganote CE, Jennings F. The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54:1496-508.
9. Menger MD, Steiner DR, Meßmer K. Microvascular ischemia-reperfusion in striated muscle: significance of "reflow paradox." Am J Physiol 1992;263:H1901-H1906.
10. Pearson JD. Pathophysiological implications of leukocytes in chronic venous insufficiency. Prog Appl Microcirc 1999;23:82-90.
11. Korthuis RJ, Gute DC. Pathophysiologic implication of leukocyte activation in chronic venous insufficiency. Medicographia 2000;22:123-32.
12. Duling BR. The preparation and use of the hamster cheek pouch for studies in the microcirculation. Microvasc Res 1973;5:423-9.
13. Svensjö E, Arfors KE, Arturson G, Rutili G. The hamster cheek pouch preparation as a model for studies of macromolecular permeability in the microvasculature. Uppsala J Med Sci 1978;83:71-9.
14. Bouskela E, Grampp W. Spontaneous vasomotion in hamster cheek pouch arterioles in varying experimental conditions. Am J Physiol 1992;262(2 Pt 2):H478-H485.
15. Takase S, Pascarella L, Lerond L, Bergan JJ, Schmid-Schönbein GW. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004;28:484-93.
16. Verbeuren TJ. Regulation of adhesion molecules: a new target for the treatment of chronic venous insufficiency Microcirculation 2000;7:S41-S48.